Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91243 | 0.83 | ANPEP (0.38) | ANPEPENPEPRNPEP | |
| SCHEMBL12112882 | 0.83 | ANPEP (0.40) | ANPEPENPEPRNPEP | |
| SCHEMBL10049243 | 0.83 | ANPEP (0.40) | ANPEPENPEPRNPEP | |
| SCHEMBL13578970 | 0.81 | ANPEP (0.39) | ANPEPENPEPRNPEP | |
| SCHEMBL15507424 | 0.81 | ANPEP (0.39) | ANPEPENPEPRNPEP | |
| SCHEMBL13191824 | 0.80 | ANPEP (0.35) | ANPEPENPEP | |
| SCHEMBL13034758 | 0.79 | ANPEP (0.38) | ANPEPENPEPRNPEP | |
| SCHEMBL12128370 | 0.79 | ANPEP (0.34) | ANPEPENPEP | |
| SCHEMBL14501183 | 0.79 | ANPEP (0.34) | ANPEPENPEPMETAP2METAP1 | |
| SCHEMBL11896813 | 0.78 | ANPEP (0.36) | ANPEPENPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9837534-B2 | Semiconductor device and fabrication method therefor | SONY CORPORATION (JP) | 2017-12-05 | — | — | US | disclosed |
| EP-2508612-B1 | Glycosylation of molecules | OXYRANE UK LTD (GB) | 2017-11-29 | — | — | EP | disclosed |
| US-20170306373-A1 | Alpha (1,3) Fucosyltransferases For Use In The Production of Fucosylated Oligosaccharides | GINKGO BIOWORKS, INC. | 2017-10-26 | — | — | US | disclosed |
| WO-2017158616-A1 | CARBAPENEM COMPOUNDS | ORCHID PHARMA LTD. (IN) | 2017-09-21 | — | — | WO | disclosed |
| US-9765389-B2 | Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection | BECTON, DICKINSON AND COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170264364-A1 | SIGNAL DECODING METHOD, SIGNAL DECODING DEVICE, AND NON-TRANSITORY COMPUTER-READABLE RECORDING MEDIUM STORING PROGRAM | PANASONIC INTELLECTUAL PROPERTY CORPORATION OF AMERICA | 2017-09-14 | — | — | US | disclosed |
| US-9757498-B2 | Bonded alumina coating for stainless steel | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2017-09-12 | — | — | US | disclosed |
| US-9752121-B2 | In vitro modelling of haematopoietic stem cell medullary nests: a tool for studying the regulation of haematopoiesis, evaluating the nesting potential of a haematopoietic graft and testing the pharmacotoxicology of medicaments | ETAT FRANCAIS (MINISTERE DE LA DEFENSE), SERVICE DE SANTE DES ARMEES (FR) | 2017-09-05 | — | — | US | disclosed |
| US-9752161-B2 | Methods of producing isoprene and a co-product | DANISCO US INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170216524-A1 | CONTINUOUS GLUCOSE MONITORING INJECTION DEVICE | BECTON, DICKINSON AND COMPANY (US) | 2017-08-03 | — | — | US | disclosed |
| US-20070093419-A1 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-7208473-B2 | Nucleic acids and protein variants of hG-CSF with granulopoietic activity | XENCOR, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7205275-B2 | Methods of treatment using specific binding agents of human angiopoietin-2 | AMGEN INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070072929-A1 | Antibacterial and/or antiprotozoal nitromidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines | EMS S.A. (BR) | 2007-03-29 | — | — | US | disclosed |
| US-20070055448-A1 | Primary rat hepatocyte toxicity modeling | GENE LOGIC INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070042941-A1 | Galectin 9-inducing factors | GALPHARMA CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070039072-A1 | Short interference RNA duplexes, when introduced into mammalian cells in culture, perform sequence-specific inhibition of target mRNA without inducing an interferon response; specific gene silencing | DHARMACON INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070027634-A1 | Molecular hepatotoxicology modeling | OCIMUM BIOSOLUTIONS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070012627-A1 | Narrow I.D. monolithic capillary columns for high efficiency separation and high sensitivity analysis of biomolecules | NORTHEASTERN UNIVERSITY | 2007-01-18 | — | — | US | disclosed |
| US-20050171067-A1 | Methods of treating disorders with group I mGluR antagonists | BROWN UNIVERSITY (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072929-A1 | Antibacterial and/or antiprotozoal nitromidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines | UMPS, PNP, UROD | ANPEP 59/4885ENPEP 412/4885RNPEP 168/4885 |
| US-20050171067-A1 | Methods of treating disorders with group I mGluR antagonists | GRM5, GRIK5, GRM2 | ANPEP 3399/4885ENPEP 1637/4885RNPEP 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.